U.S., April 28 -- ClinicalTrials.gov registry received information related to the study (NCT07552077) titled 'A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)' on April 20.
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Angiokeratomas
Intervention:
DRUG: PTX-022
topical administration of PTX-022
Recruitment Status: RECRUITING
Sponsor: Palvella Therapeutics, Inc.
Disclaimer: Curated by HT Syndication....